Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
The supply disruption of Takeda Pharmaceutical’s cancer drug Leuplin (leuprorelin) has caused shortages of its widely used six-month depot formulation, leading to a rise in copay and hospital visit costs for some patients who had to switch to the drug’s…
To read the full story
Related Article
- Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
- Takeda Faces New Problem on Leuplin, System Glitch Cripples Supply of 1, 3-Month Products
September 7, 2021
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
BUSINESS
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
- NTT Data, Kindai Hospital Validate RWD-Based Patient Screening Technology
May 26, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…